Navigation Links
Updated Results from Phase 2 Trial Demonstrate Prolonged Hematologic Relapse-Free Survival of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia
Date:6/14/2010

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL).  Results of the analysis demonstrate that a prolonged hematologic relapse free survival was observed in patients treated with blinatumomab. As of April 2010, six of nine evaluable, MRD responding, non-transplanted patients were in hematologic remission, ranging up to 23 months.  Historical experience suggests that the majority of patients with MRD following front-line chemotherapy who do not receive a transplant will relapse within one year.  Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

Dr. Max Topp, Department of Internal Medicine II, University of Wuerzburg presented the study findings on June 12, 2010 in an oral presentation (abstract # 0598) at the 15th Annual Congress of the European Hematology Association (EHA) in Barcelona, Spain.

"Adult acute lymphoblastic leukemia is a difficult to treat disease that has seen no meaningful improvement in decades," said Dr. Topp.  "These data clearly demonstrate that blinatumomab has the potential to fundamentally change the outcome for patients with ALL."

Phase 2 Study Design

This multi-center Phase 2 study evaluated the efficacy and safety of blinatumomab in ad
'/>"/>

SOURCE Micromet, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
2. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
3. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
4. Newly Updated Pharmacy State Law Compendium Available
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
6. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
7. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
8. IDM Pharma Announces Updated Data From Mifamurtide (L-MTP-PE) Compassionate Access Program
9. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
10. ORTHO EVRA(R) Prescribing Information Updated
11. Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... CHENGDU, China, Dec. 24, 2014 /PRNewswire/  -- Tianyin ... a pharmaceutical company that specializes in the patented ... and active pharmaceutical ingredients (API) released unaudited preliminary ... year 2015. Fiscal Year 2015 Ended ... was $9.7 million compared with $14.7 million in ...
(Date:12/24/2014)... 24, 2014  The International Trade Commission (ITC) issued its ... BMC Medical. In a notice issued on December 23, the ... patent on its humidifier was invalid. BMC President, ... "We are very excited with the ITC,s decision in this ... have taken since the very beginning on the key patents ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. ... chronic illnesses can receive effective, less expensive care from a ... to a team of dedicated health care professionals, a new ... ill and need either hospitalization or a trip to the ... home clinic at the University of Texas in Houston versus ...
(Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... closing in on a "fountain of youth" drug that can ... older adults, a new study suggests. Seniors received a ... that targets a genetic signaling pathway linked to aging and ... The experimental medication, a version of the drug ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Plugin creators ... ProFire 5k. A fully customizable business presentation tool made ... “Adding the ProFire 5k business tool, users can now ... Austin, CEO of Pixel Film Studios. “ProFire 5k gives ... style to add professionalism to a presentation” , Pixel ...
(Date:12/24/2014)... AlignLife of Wauwatosa loves helping those in the ... holiday season, AlignLife looks forward to their annual toy drive. ... Mahalko-Leonhardt, owner of AlignLife. "It brings our patients as well ... able to give kids toys for Christmas who would be ... of our patients." , The 70 toys were donated to ...
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and retailer, ... $150 . All these items are brand new; they are ... been updated with the new range of high quality prom ... All iFitDress.com’s designs are made according to the latest trends. ... Every outfit from the company is handpicked by skilled tailors. ...
Breaking Medicine News(10 mins):Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2
... Association,of Realtors testified at the Senate Finance Committee hearing ... serve the needs of,its self-employed members. Nearly 30 percent ... primary reason - 84 percent of Realtors who do,not ... believe that tax incentives for the self-employed and for ...
... Inc. (APCapital) (Nasdaq: ACAP ) today announced net,income ... for the third,quarter of 2007. For the first nine ... million, or $3.54 per diluted common share. At,September 30, ... on,10,575,799 shares outstanding, an increase of 10.1% from $23.26 ...
... a Phase II Trial to Evaluate an Immunomodulatory Cell ... York, NY October 25, 2007 The ... Osiris Therapeutics, Inc. (NASDAQ:OSIR) to support a Phase II ... to preserve and regenerate insulin-producing cells in patients newly ...
... in Cancer Control, Volunteerism and,Humanitarianism, ATLANTA, ... and dedication have helped reduce the burden ... American Cancer Society for their work,in cancer ... Society, the nation,s largest voluntary health organization, ...
... show Masimo provides unique benefits in pulse oximetry, ... hemodynamic monitoring IRVINE, Calif., Oct. 25 /PRNewswire-FirstCall/ ... and Low Perfusion pulse oximetry,reported that multiple independent ... presented last week at the 2007 American Society ...
... new information that may help to improve the use of ... vessels in tumors, a process called angiogenesis that is critical ... present there are no reliable methods for determining whether they ... a patient will benefit (or not) from treatment. , ...
Cached Medicine News:Health News:Nearly 30 Percent of Realtors(R) Lack Health Insurance 2Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 2Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 3Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 4Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 5Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 6Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 7Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 8Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 9Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 10Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 11Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 12Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 13Health News:JDRF Partners with Osiris to evaluate an immunomodulatory cell therapy product for type 1 diabetes 2Health News:American Cancer Society Honors Outstanding Contributions to Fight Against Cancer 2Health News:American Cancer Society Honors Outstanding Contributions to Fight Against Cancer 3Health News:American Cancer Society Honors Outstanding Contributions to Fight Against Cancer 4Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 2Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 3Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 4Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 5Health News:Breaking Studies - Masimo's Technologies the Focus of Multiple Clinical Studies at Last Week's American Society of Anesthesiologists' Annual Meeting 6Health News:Study shows blood markers can help choose best dose for antiangiogenic drugs 2Health News:Study shows blood markers can help choose best dose for antiangiogenic drugs 3
... unique Electro-4 design allows "Four gels in one ... possible to run 200 samples or more in ... four horizontal gels. To ensure even migration, the ... of gels being run. Ideal for high throughput ...
... may be formed directly on the UV-transparent gel ... agarose as it cools, or outside the unit ... Gel is 7.5cm wide 10cm long. Different colors ... (e.g., RNA only). Combs and tape are not ...
... gel is made of high quality PMMA. It features ... protection device.Combs, gel tray and cables are all included ... 6.5x6 (cm), 200 ... 2 (9-well) • 2 ...
... the HE 33 Mini Submarine Unit for nucleic acid ... is designed for very fast separations of DNA restriction ... as a heat-sink. Fill the base with coolant and ... either keeping the unit in a freezer or by ...
Medicine Products: